Meta-Analysis of the Efficacy of Levosimendan in the Treatment of Severe Sepsis Complicated with Septic Cardiomyopathy
DOI:
https://doi.org/10.59958/hsf.6439Keywords:
levosimendan, sepsis, cardiomyocytes, LVEF, cardiac outputAbstract
Introduction: Sepsis is a medical condition characterized by acute organ dysfunction and uncontrolled inflammation. Organ dysfunction in sepsis is the primary cause of mortality in patients with myocardial dysfunction. Levosimendan is a vasodilating and inotropic agent used in patients with acute heart failure and has resulted in decreased morbidity and mortality in these patients. Our main objective is to examine levosimendan's efficacy in treating severe sepsis complicated with septic cardiomyopathy. Methods: We systematically searched five databases, PubMed, Web of Science, Embase, Cochrane Library and BioMed Central, for articles and publications from their inception to 2023. Our study adopted the PICOS approach in identifying suitable publications during the systematic search. Inclusion criteria included randomized, controlled trials utilizing levosimendan in adult patients diagnosed with septic shock or severe sepsis. We excluded non-English publications and non-randomized controlled trials. The Newcastle-Ottawa scale (NOS) scale was used to assess the methodological quality, while the risk of bias was assessed through the Cochrane Risk of bias tool. All statistical analyses were performed using RevMan version 5.4. Results: Eight studies met the eligibility criteria and were included in the analysis. There was a statistically significant positive effect on cardiac input in patients treated with levosimendan compared to those treated with dobutamine (p < 0.001). Similarly, there were positive effects on left ventricular ejection fraction (LVEF) (p < 0.001) and left ventricular stroke work index (LVSWI) (p < 0.001). We observed a significant reduction in mortality (p < 0.01) and serum levels of lactic acid (p < 0.01). Discussion: Levosimendan is a calcium sensitizer associated with an influx of calcium ions and activation of ATP-dependent potassium channels that increases myocardial contractility contractions, enhances vasodilation and improves oxygen supply to the cells and tissues. Conclusion: Levosimendan is highly efficacious and safe in the management of sepsis and sepsis-induced cardiomyopathy.
References
Fani F, Regolisti G, Delsante M, Cantaluppi V, Castellano G, Gesualdo L, et al. Recent advances in the pathogenetic mechanisms of sepsis-associated acute kidney injury. Journal of Nephrology. 2018; 31: 351–359.
Ketcham SW, Sahai YR, Miller HC, Bolig TC, Ludwig A, Co I, et al. Causes and characteristics of death in patients with acute hypoxemic respiratory failure and acute respiratory distress syndrome: a retrospective cohort study. Critical Care. 2020; 24: 1–9.
Antcliffe DB, Santhakumaran S, Orme RML, Ward JK, Al-Beidh F, O'Dea K, et al. Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial. Intensive Care Medicine. 2019; 45: 1392–1400.
Silvetti S, Belletti A, Bianzina S, Momeni M. Effect of Levosimendan Treatment in Pediatric Patients With Cardiac Dysfunction: An Update of a Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Cardiothoracic and Vascular Anesthesia. 2022; 36: 657–664.
Conti N, Gatti M, Raschi E, Diemberger I, Potena L. Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap. Drug Design, Development and Therapy. 2021; 15: 3391–3409.
Gonçalves AV, Reis JP, Timóteo AT, Soares R, Pereira-da-Silva T, Gomes V, et al. Outpatient 6-Hour Levosimendan Treatment as a Bridge to Heart Transplant. Arquivos Brasileiros De Cardiologia. 2023; 120: e20220205.
Putzu A, Belletti A, Zangrillo A. Levosimendan in Sepsis. The New England Journal of Medicine. 2017; 376: 798–799.
Preau S, Vodovar D, Jung B, Lancel S, Zafrani L, Flatres A, et al. Energetic dysfunction in sepsis: a narrative review. Annals of Intensive Care. 2021; 11: 1–21.
Qu C, Feng W, Zhao Q, Liu Q, Luo X, Wang G, et al. Effect of Levosimendan on Acute Decompensated Right Heart Failure in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Frontiers in Medicine. 2022; 9: 778620.
Martin L, Derwall M, Thiemermann C, Schürholz T. Heart in sepsis: molecular mechanisms, diagnosis and therapy of septic cardiomyopathy. Anaesthesist. 2017; 66: 479–490. (In German)
Chang W, Xie JF, Xu JY, Yang Y. Effect of levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials. BMJ Open. 2018; 8: e019338.
Pan J, Yang YM, Zhu JY, Lu YQ. Multiorgan Drug Action of Levosimendan in Critical Illnesses. BioMed Research International. 2019; 2019: 9731467.
Yang F, Zhao LN, Sun Y, Chen Z. Levosimendan as a new force in the treatment of sepsis-induced cardiomyopathy: mechanism and clinical application. The Journal of International Medical Research. 2019; 47: 1817–1828.
KocaU, Demirdöven BT. Levosimendan in sepsis. Journal of Clinical Intensive Care and Medicine. 2020; 5: 020–021.
Tsolaki V, Zakynthinos GE, Papanikolaou J, Vazgiourakis V, Parisi K, Fotakopoulos G, et al. Levosimendan in the Treatment of Patients with Severe Septic Cardiomyopathy. Life (Basel, Switzerland). 2023; 13: 1346.
Chen YW, Lee WC, Wu PJ, Fang HY, Fang YN, Chen HC, et al. Early Levosimendan Administration Improved Weaning Success Rate in Extracorporeal Membrane Oxygenation in Patients With Cardiogenic Shock. Frontiers in Cardiovascular Medicine. 2022; 9: 912321.
Morelli A, Donati A, Ertmer C, Rehberg S, Lange M, Orecchioni A, et al. Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study. Critical Care (London, England). 2010; 14: R232.
Meng JB, Hu MH, Lai ZZ, Ji CL, Xu XJ, Zhang G, et al. Levosimendan Versus Dobutamine in Myocardial Injury Patients with Septic Shock: A Randomized Controlled Trial. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2016; 22: 1486–1496.
Liu DH, Ning YL, Lei YY, Chen J, Liu YY, Lin XF, et al. Levosimendan versus dobutamine for sepsis-induced cardiac dysfunction: a systematic review and meta-analysis. Scientific Reports. 2021; 11: 20333.
Vaitsis J, Michalopoulou H, Thomopoulos C, Massias S, Stamatis P. Use of levosimendan in myocardial dysfunction due to sepsis. Critical Care. 2009; 13: 165.
Selçuk AA. A Guide for Systematic Reviews: PRISMA. Turkish Archives of Otorhinolaryngology. 2019; 57: 57–58.
Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Database of Systematic Reviews. 2019; 10: ED000142.
Peterson J, Welch V, Losos M, Tugwell PJ. The Newcastle-Ottawa scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. 2011; 2: 1–2.
Morelli A, De Castro S, Teboul JL, Singer M, Rocco M, Conti G, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Medicine. 2005; 31: 638–644.
Hajjej Z, Meddeb B, Sellami W, Labbene I, Morelli A, Ferjani M. Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock: A Randomized Controlled Pilot Study. Shock (Augusta, Ga.). 2017; 48: 307–312.
Torraco A, Carrozzo R, Piemonte F, Pastore A, Tozzi G, Verrigni D, et al. Effects of levosimendan on mitochondrial function in patients with septic shock: a randomized trial. Biochimie. 2014; 102: 166–173.
Memiş D, Inal MT, Sut N. The effects of levosimendan vs dobutamine added to dopamine on liver functions assessed with noninvasive liver function monitoring in patients with septic shock. Journal of Critical Care. 2012; 27: 318.e1–6.
Alhashemi JA, Alotaibi QA, Abdullah GM, Shalabi SA. Levosimendan vs dobutamine in septic shock. Journal of Critical Care. 2009; 24: e14–e15.
Legrand M, De Backer D, Dépret F, Ait-Oufella H. Recruiting the microcirculation in septic shock. Annals of Intensive Care. 2019; 9: 1–4.
Dubin A, Lattanzio B, Gatti L. The spectrum of cardiovascular effects of dobutamine - from healthy subjects to septic shock patients. Revista Brasileira De Terapia Intensiva. 2017; 29: 490–498.
Razazi K, Labbé V, Laine L, Bedet A, Carteaux G, de Prost N, et al. Hemodynamic effects and tolerance of dobutamine for myocardial dysfunction during septic shock: An observational multicenter prospective echocardiographic study. Frontiers in Cardiovascular Medicine. 2022; 9: 951016.
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Medicine. 2017; 43: 304–377.
Ospina-Tascón GA, Calderón-Tapia LE. Inodilators in septic shock: should these be used? Annals of Translational Medicine. 2020; 8: 796.
Weiss SL, Peters MJ, Alhazzani W, Agus MS, Flori HR, Inwald DP, et al. Executive summary: surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Medicine. 2020; 46: 1–9.
Hu Y, Wei Z, Zhang C, Lu C, Zeng Z. The effect of levosimendan on right ventricular function in patients with heart dysfunction: A systematic review and meta-analysis. Scientific Reports. 2021; 11: 24097.
Rysz S, Lundberg J, Nordberg P, Eriksson H, Wieslander B, Lundin M, et al. The effect of levosimendan on survival and cardiac performance in an ischemic cardiac arrest model–Ablinded randomised placebo-controlled study in swine. Resuscitation. 2020; 150: 113–120.
Beesley SJ, Weber G, Sarge T, Nikravan S, Grissom CK, Lanspa MJ, et al. Septic Cardiomyopathy. Critical Care Medicine. 2018; 46: 625–634.
Jentzer JC, Vallabhajosyula S, Khanna AK, Chawla LS, Busse LW, Kashani KB. Management of Refractory Vasodilatory Shock. Chest. 2018; 154: 416–426.
Klaeboe LG, Edvardsen T. Echocardiographic assessment of left ventricular systolic function. Journal of Echocardiography. 2019; 17: 10–16.
Bayram E, Gulcu O, Aksu U, Aksakal E, Birdal O, Kalkan K. Evaluating the Association Between the Three Different Ejection Fraction Measurement Techniques and Left Ventricle Global Strain. The Eurasian Journal of Medicine. 2018; 50: 173–177.
Giannelli V, Roux O, Laouénan C, Manchon P, Ausloos F, Bachelet D, et al. Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. Journal of Hepatology. 2020; 72: 463–471.
Pu WL, Zhang MY, Bai RY, Sun LK, Li WH, Yu YL, et al. Anti-inflammatory effects of Rhodiolarosea L.: A review. Biomedicine & Pharmacotherapy. 2020; 121: 109552.
Rissel R, Gosling M, Kamuf J, Renz M, Ruemmler R, Ziebart A, et al. Levosimendan Ameliorates Cardiopulmonary Function but Not Inflammatory Response in a Dual Model of Experimental ARDS. Biomedicines. 2022; 10: 1031.
